[Cytokines and septic shock. New perspectives on its treatment].
Zamora Madaria
E
E
D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D016207:Cytokines / Q000502:physiology*; D004198:Disease Susceptibility; D004285:Dogs; D004731:Endotoxins / Q000009:adverse effects / Q000276:immunology; D016905:Gram-Negative Bacterial Infections / Q000628:therapy; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology / Q000627:therapeutic use; D008070:Lipopolysaccharides / Q000009:adverse effects / Q000276:immunology; D051379:Mice; D008809:Mice, Inbred C3H; D051381:Rats; D012772:Shock, Septic / Q000503:physiopathology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000906:Antibodies; D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D016207:Cytokines; D004731:Endotoxins; D007075:Immunoglobulin M; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha
Citocinas y shock séptico. Nuevas perspectivas en su tratamiento.